Literature DB >> 10102004

Prostate cancer: 12. The economic burden.

S A Grover1, H Zowall, L Coupal, M D Krahn.   

Abstract

Entities:  

Mesh：

Year:  1999        PMID： 10102004      PMCID： PMC1230115     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  34 in total

1.  Orchidectomy and hormonal therapy of prostate cancer.

Authors:  T To; N Iscoe; L Klotz; C D Naylor
Journal:  Can J Urol       Date:  1995-01       Impact factor: 1.344

Review 2.  Prostate cancer: where are we and where are we going?

Authors:  S R Denmeade; J T Isaacs
Journal:  Br J Urol       Date:  1997-03

3.  The impending Canadian prostate cancer epidemic.

Authors:  H I Morrison; I B MacNeill; D Miller; I Levy; L Xie; Y Mao
Journal:  Can J Public Health       Date:  1995 Jul-Aug

4.  Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer.

Authors:  C Mettlin; G W Jones; G P Murphy
Journal:  CA Cancer J Clin       Date:  1993 Mar-Apr       Impact factor: 508.702

5.  CT screening for comorbid disease in patients with prostatic carcinoma: is it cost-effective?

Authors:  H P Forman; J P Heiken; J A Brink; H S Glazer; L A Fox; B L McClennan
Journal:  AJR Am J Roentgenol       Date:  1994-05       Impact factor: 3.959

6.  Early hospital discharge after radical retropubic prostatectomy: impact on cost and complication rate.

Authors:  M R Licht; E A Klein
Journal:  Urology       Date:  1994-11       Impact factor: 2.649

7.  A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone.

Authors:  A J McEwan; G A Amyotte; D G McGowan; J A MacGillivray; A T Porter
Journal:  Nucl Med Commun       Date:  1994-07       Impact factor: 1.690

8.  Follow-up prostate cancer treatments after radical prostatectomy: a population-based study.

Authors:  G L Lu-Yao; A L Potosky; P C Albertsen; J H Wasson; M J Barry; J E Wennberg
Journal:  J Natl Cancer Inst       Date:  1996-02-21       Impact factor: 13.506

9.  Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy.

Authors:  J H Gurwitz; J Avorn; R L Bohn; R J Glynn; M Monane; H Mogun
Journal:  JAMA       Date:  1994-09-14       Impact factor: 56.272

10.  Chest radiography in patients with early stage prostatic carcinoma. Effect on treatment planning and cost analysis.

Authors:  H P Forman; L A Fox; H S Glazer; B L McClennan; D C Anderson; S S Sagel
Journal:  Chest       Date:  1994-10       Impact factor: 9.410
View more
  14 in total

1.  Prostate cancer from a patient's perspective.

Authors:  D Grundy
Journal:  CMAJ       Date:  1999-06-29       Impact factor: 8.262

2.  Understanding obesity.

Authors:  J D Douketis
Journal:  CMAJ       Date:  1999-06-29       Impact factor: 8.262

3.  The more the better?

Authors:  M Simunovic; T To; B Langer
Journal:  CMAJ       Date:  1999-06-29       Impact factor: 8.262

4.  Understanding obesity.

Authors:  T M Stein
Journal:  CMAJ       Date:  1999-06-29       Impact factor: 8.262

5.  PSA screening: a view from the front lines. North York General-Branson Practice-Based Small Group.

Authors:  M Greiver; N Rosen
Journal:  CMAJ       Date:  2000-03-21       Impact factor: 8.262

6.  Cost study of the clinical management of prostate cancer in France: results on the basis of population-based data.

Authors:  Laurent Molinier; Christel Castelli; Eric Bauvin; Xavier Rebillard; Michel Soulié; Jean-Pierre Daurès; Pascale Grosclaude
Journal:  Eur J Health Econ       Date:  2010-06-13

7.  The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.

Authors:  S A Grover; L Coupal; H Zowall; R Rajan; J Trachtenberg; M Elhilali; M Chetner; L Goldenberg
Journal:  CMAJ       Date:  2000-04-04       Impact factor: 8.262

8.  The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.

Authors:  S A Grover; L Coupal; H Zowall; R Rajan; J Trachtenberg; M Elhilali; M Chetner; L Goldenberg
Journal:  CMAJ       Date:  2000-04-04       Impact factor: 8.262

Review 9.  Quality of life and economic considerations in the management of prostate cancer.

Authors:  Marco Turini; Alberto Redaelli; Paola Gramegna; Davide Radice
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

10.  Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population.

Authors:  Nicole M Engel-Nitz; Berhanu Alemayehu; David Parry; Faith Nathan
Journal:  Cancer Manag Res       Date:  2011-07-04       Impact factor: 3.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.